RCSB PDB - 3NDM: Crystal structure of Rho-Associated Protein Kinase (ROCK1) with a potent isoquinolone derivative (original) (raw)

Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.

[Bosanac, T.](/search?q=citation.rcsb%5Fauthors:Bosanac, T.), [Hickey, E.R.](/search?q=citation.rcsb%5Fauthors:Hickey, E.R.), [Ginn, J.](/search?q=citation.rcsb%5Fauthors:Ginn, J.), [Kashem, M.](/search?q=citation.rcsb%5Fauthors:Kashem, M.), [Kerr, S.](/search?q=citation.rcsb%5Fauthors:Kerr, S.), [Kugler, S.](/search?q=citation.rcsb%5Fauthors:Kugler, S.), [Li, X.](/search?q=citation.rcsb%5Fauthors:Li, X.), [Olague, A.](/search?q=citation.rcsb%5Fauthors:Olague, A.), [Schlyer, S.](/search?q=citation.rcsb%5Fauthors:Schlyer, S.), [Young, E.R.](/search?q=citation.rcsb%5Fauthors:Young, E.R.)

(2010) Bioorg Med Chem Lett 20: 3746-3749

• PubMed: 20471253 Search on PubMed

• DOI: https://doi.org/10.1016/j.bmcl.2010.04.069

• PubMed Abstract:
  The discovery and SAR of a series of beta-aryl substituted pyrrolidine 2H-isoquinolin-1-one inhibitors of Rho-kinase (ROCK) derived from 2 is herein described. SAR studies have shown that aryl groups in the beta-position are optimal for potency. Our efforts focused on improving the ROCK potency of this isoquinolone class of inhibitors which led to the identification of pyrrolidine 32 which demonstrated a 10-fold improvement in aortic ring (AR) potency over 2.

Organizational Affiliation:

Department of Medicinal Chemistry, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368, USA. todd.bosanac@boehringer-ingelheim.com